Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasHodgkin LymphomaIndolent LymphomasDiseaseAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C88.0-C91.0-C91.1-MeSHLymphoma, Mantle-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceGADOLIN: OBIN1000/BEND90, foll. Lymphoma °I-IIIa, C1 (PID710) -|- C2-6 (PID724) -|- maint. (PID725)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)OBIN-CHOP (OBIN1000/CYCL750/DOXO50/VNCR2/PRED100), foll. Lymphoma °I-IIIa, C1 (PID1171) -|- C2-6 (PID1172) -|- C7-8 (PID1174) -|- maint. (PID1173)OBIN-CVP (OBIN1000/CYCL750/VNCR2/PRED100), foll. Lymphoma °I-IIIa, C1 (PID2416) -|- C2-8 (PID2417) -|- maint. (PID2419)RITU375 Ind., foll. Lymphoma °I-IIIa A (PID300) -|- maint. B (PID301)RITU375/LENA20, foll. Lymphoma °I-IIIa, C1 (PID1529) -|- C2-6 (PID1530) -|- C7-12 (PID1531) -|- maint. (PID295)RITU375/LENA20, ind. B-NHL ind. (PID309) -|- LENA20 maint. (PID329)ChemotherapyChemo-substanceBendamustineBortezomibCarboplatinChlorambucilCyclophosphamideDexamethasoneDoxorubicinFludarabineGemcitabineIdelalisibLenalidomideMitoxantroneObinutuzumabPrednisoloneRituximabVincristineChemo-substanceBendamustineBortezomibCarboplatinChlorambucilCyclophosphamideDexamethasoneDoxorubicinFludarabineGemcitabineIdelalisibLenalidomideMitoxantroneObinutuzumabPrednisoloneRituximabVincristineChemo-substanceBendamustineBortezomibCarboplatinChlorambucilCyclophosphamideDexamethasoneDoxorubicinFludarabineGemcitabineIdelalisibLenalidomideMitoxantroneObinutuzumabPrednisoloneRituximabVincristineChemo-substanceBendamustineBortezomibCarboplatinChlorambucilCyclophosphamideDexamethasoneDoxorubicinFludarabineGemcitabineIdelalisibLenalidomideMitoxantroneObinutuzumabPrednisoloneRituximabVincristineNo. Substances1245 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronMesnaPantoprazoleParacetamolPegfilgrastimPrednisoloneNo. Substances23456789Protocol classificationTherapy classificationalternativecurrent standardindividual (author)IntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineTherapy phaseConsolidationInductionMaintenanceTherapy intentionconsolidationcurativedisease controlpalliativeRisksAlopeciaAnemia Hb below 8g/dlAstheniaCardiotoxicityDiarrheaDyspneaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHypertensionHyponatremiaHypotensionIncrease AminotransferasesInfectionsInfusion ReactionMucositisNeuropathyNeurotoxicityNeutropeniaPainPneumoniaPruritusRashSepsisThrombocytopenia below 50 000/µlTumor Lysis Syndrome only studiesPublicationAuthorBaiocchi RACzuczman MSDavies AForstpointnerGhielmini MGopal AGopal AKHerold MHerold M HiddemannKönig LMarcus RMorschhauser FRobinson KSRummel MJSalles GScholz CWSehn LTuscano JMvan Oers MHJWitzig TEDiseaseFoll. L. °I-II, Marginalzonen-L., kleines lymphozyt. L., ECOG 0-2, mind. eine Vortherapiefoll. L. °I-II, Marginalzonen-L., kleines lymphozyt. Lymphom, mind. eine Vortherapie, ECOG 0-2Foll. L. °I-IIIa, kleines lymphozyt. L., Marginalzonenl., lymphoplasmoyt. L., Drittlinie bei Rituximab- u Alkylanz-RefraktäritätFoll. Lymphom, Grad 1-2, Stadium III oder IV mit Therapieindikation, ErstbehandlungFoll. Lymphom, Grad I-III, ECOG 0-2, Erst- und ZweitlinieFoll. Lymphom, Grad I-III, Stadium III oder IV mit Therapieindikation, ECOG 0-2, ErstlinieFoll. Lymphom, Grad I-III, Stadium III und IV, Zweit- bis Drittlinie, ECOG 0-2Foll. Lymphom, Grad I-IIIa, ECOG 0-2, nach Ansprechen auf R-CHOP, R-CVP oder R-FCMFoll. Lymphom, Grad I-IIIa, Stadium II bis IV mit Therapieindikation, Patienten älter als 50, ErstlinieFoll. Lymphom, Stadium I-IIFoll. Lymphom Grad 1-2, MCL, lymphoplasmozytisches Lymphom, Therapieindikation, Erstlinie ECOG 0-2Foll. Lymphom Grad 1-2, Stadium III und IV, ECOG 0-2, nach Ansprechen auf ErstlinieFoll. Lymphom Grad I-III, Progress innerhalb von 6 Monaten oder nach Nichtansprechen auf Rituximab-InduktionFollikuläres Lymphom, Grad I-III, ECOG 0-2, Erst- und ZweitlinieFollikuläres Lymphom, kleines lymphozytische Lymphom, Erst- bis Fünftlinie, Karnofsky-Index größer 60%fortgeschrittenes follikuläres Lymphom °I-IIIa, Stadium III oder IV, Erstlinie, ECOG 0-2MCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieMCL, follikuläres Lymphom, Grad 1 und 2, Zweitlinie oder höherMCL, follikuläres Lymphom, lymphoplasmozytisches Lymphom, Zweitlinierezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2Rituximab refraktäre indolente B-NHL, ECOG 0-2OriginAbteilung für Hämatologie, Onkologie und Tumor Immunologie, Charité Berlin, DeutschlandAddenbrooke's Hospital, Cambridge, EnglandBritish Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada, GADOLIN trialCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCentre Hospitalier Unciversitaire, Lille, FrankreichDepartment of Medicine, Division of Medical Oncology, University of Washington School of Medicine, USADepartment of Radiation Oncology, University of Heidelberg, Heidelberg, GermanyEast German Study GroupEORTC, HOVON, NCIC, CTG, BNLI, ALLG, NLGGerman Low-Grade Lymphoma Study GroupHelios Klinikum, Hämatologie/Onkologie, Erfurt, Deutschland, Studie OSHO# 19Hospices Civils de Lyon, Université Claude Bernard, Frankreich. PRIMA StudieInstitute of Oncology, Bellinzona, SchweizKings College Hospital, Denmark Hill, London, UK, GALLIUM trialMayo Clinic, Rochester, USAOhio State University, Columbus, Ohio, USAQE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaRoswell Park Cancer Institute, Buffallo, NY, USAStudy Group indolent Lymphomas (StiL)UC Davis Cancer Center, Sacramento, USAUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAProtocols in Revision 34 protocols foundIdelalisib 150, indolent B-non-Hodgkin Lymphoma (PID308 V1.2)Obinutuzumab 1000 - CHOP - Obinutuzumab 1000, follicular lymphoma °I-IIIa, maintenance (PID1173 V1.0)Obinutuzumab 1000 - CHOP - Obinutuzumab 1000, follicular lymphoma °I-IIIa, cycle 7-8 (PID1174 V1.0)Obinutuzumab 1000 / Bendamustine 90 - Obinutuzumab 1000 Maintenance, follicular lymphoma °I-IIIa (PID725 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 1 (PID710 V1.0)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 2-6 (PID724 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 1 (PID1171 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 2-6 (PID1172 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa, cycle 1. (PID2416 V1.0)Obinutuzumab 1000 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 100, follicular Lymphoma grade I-IIIa, cycle 2-8 (PID2417 V1.1)Obinutuzumab 1000, follicular lymphoma °I-IIIa, maintenance (PID2419 V1.0)Obinutuzumab 1000, follicular Lymphoma °I-IIIa, cycle 7-8 (PID2418 V1.0)R-BOP - Rituximab 375 / Bendamustine 60 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID297 V1.0)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, follicular lymphoma grade I-IIIa (PID294 V1.0)R-COP - Rituximab 375 / Cyclophosphamide 400 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID298 V1.0)R-CVP - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / Prednisolone 40, follicular lymphoma grade I-IIIa (PID296 V1.0)R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681 V1.0)R-MCP - Rituximab 375 / Mitoxantrone 8 / Chlorambucil 3 / Prednisolone 25, follicular lymphoma grade I-IIIa (PID299 V1.1)RITU375/FLUD25, follicular lymphoma and indolent B-NHL (PID304 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan consolidation, follicular lymphoma grade I-IIIa (PID305 V1.0)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan, follicular lymphoma grade I-IIIa (PID303 V1.0)Rituximab 250 / 90 Yttrium-Ibritumomab Tiuxetan, follicular lymphoma grade I-IIIa, second-line (PID306 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270 V1.0)Rituximab 375 / Bortezomib 1.3, Mantle Cell Lymphoma and Follicular Lymphoma (PID278 V1.0)Rituximab 375 / Fludarabine 25 / Cyclophosphamide 200 / Mitoxantrone 8, follicular lymphoma and Mantle Cell Lymphoma (PID272 V1.1)Rituximab 375 / lenalidomide 20 - Lenalidomide 20 maintenance, indolent B non-Hodgkin Lymphoma induction (PID329 V1.0)Rituximab 375 / Lenalidomide 20, indolent B non-Hodgkin Lymphoma, induction (PID309 V1.0)Rituximab 375 / Radiation, follicular lymphoma (PID2333 V1.0)Rituximab 375 maintenance after first-line, grade I-IIIa follicular lymphoma (PID295 V1.0)Rituximab 375 maintenance after Rituximab induction, follicular lymphoma grade I-IIIa part B (PID301 V1.0)Rituximab 375 maintenance after second-line, grade I-IIIa follicular lymphoma (PID302 V1.0)Rituximab 375 induction, follicular lymphoma grade I-IIIa part A (PID300 V1.0)
